wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q40846805-0C5085F1-E7B1-4675-A081-8C503210776E
Q40846805-0C5085F1-E7B1-4675-A081-8C503210776E
BestRank
Statement
http://www.wikidata.org/entity/statement/Q40846805-0C5085F1-E7B1-4675-A081-8C503210776E
Concurrent sorafenib therapy extends the interval to subsequent TACE for patients with unresectable hepatocellular carcinoma.
P2860
Q40846805-0C5085F1-E7B1-4675-A081-8C503210776E
BestRank
Statement
http://www.wikidata.org/entity/statement/Q40846805-0C5085F1-E7B1-4675-A081-8C503210776E
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
bdbac4b5ed724e799dd764b7accbc88e20ca1844
P2860
Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma.